Login / Signup

PD-1 or PD-L1 Blockade Adds Little to Combination of BRAF and MEK Inhibition in the Treatment of BRAF V600-Mutated Melanoma.

Margaret K CallahanPaul B Chapman
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Keyphrases
  • wild type
  • metastatic colorectal cancer
  • combination therapy
  • cell proliferation
  • signaling pathway
  • smoking cessation
  • basal cell carcinoma